The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Systemic Therapy for Colorectal Cancer
Abstract
Colorectal cancer remains the second most common cause of cancer-related deaths in this country. Although colorectal cancer is best managed by a multidisciplinary team of surgical, radiation, and medical oncologists, cytotoxic therapy remains the backbone of treatment in the metastatic disease setting. In addition to cytotoxic therapies, vascular-targeted therapies and epidermal growth factor receptor (EGFR)–targeted therapies for selected patients with metastatic colorectal cancer improve outcomes for patients with metastatic colorectal cancer. Growing understanding of various biological subsets of colorectal cancer, including BRAF V600E mutant and mismatch repair–deficient colorectal cancers, is expanding treatment opportunities for patients and is the focus of ongoing research. This review contains 4 tables and 57 references. Key Words: chemotherapy, colorectal cancer, fluoropyrimidines, immunotherapy, metastatic, mismatch repair–deficient colorectal cancer, targeted therapy, topoisomerase inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
American Joint Committee On Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88443-1 · Cited by 1,386
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Cellular and molecular pharmacology of oxaliplatin.
Raymond, É., Faivre, S. J., Chaney, S. G., WOYNAROWSKI, J. M., & Cvitkovic, E. (2002) · PubMed · Cited by 576
Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond, É., Faivre, S. J., WOYNAROWSKI, J. M., & Chaney, S. G. (1998) · PubMed · Cited by 520
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Grothey, A. (2002) · Medical Entomology and Zoology · Cited by 167
Kornmann, M., Schwabe, W., Sander, S., Kron, M., Sträter, J., Polat, S., Kettner, E., Weiser, H. F., Baumann, W., Schramm, H., et al. (2003) · PubMed · Cited by 157
Saltz, L. B., Niedzwiecki, D., Hollis, D. R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3500 · Cited by 104
Cited by
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Detection and quantification of mutations in the plasma of patients with colorectal tumors
Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507904102 · Cited by 1,188
Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure
Tomlinson, J. S., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kornprat, P., Gonen, M., Kemeny, N., Brennan, M. F., Blumgart, L. H., & D'Angelica, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0833 · Cited by 1,187
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
Mima, K., Nishihara, R., Qian, Z. R., Cao, Y., Sukawa, Y., Nowak, J. A., Yang, J., Dou, R., Masugi, Y., Song, M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310101 · Cited by 1,080
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Physical activity and survival after colorectal cancer diagnosis
Meyerhardt, J. A., Giovannucci, E. L., Holmes, M. D., Chan, A. T., Chan, J. A., Colditz, G. A., & Fuchs, C. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0855 · Cited by 857
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
de Jong, M. C., Pulitano, C., Ribero, D., Strub, J., Mentha, G., Schulick, R. D., Choti, M. A., Aldrighetti, L., Capussotti, L., & Pawlik, T. M. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b4539b · Cited by 783
Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Aspirin Use and Survival After Diagnosis of Colorectal Cancer
Chan, A. T. (2009) · JAMA · doi:10.1001/jama.2009.1112 · Cited by 557
Ajani, J. A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., Vynnychenko, I., Garin, A., Lang, I., & Falcon, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4706 · Cited by 550
Yang, A. D., Fan, F., Camp, E. R., van Buren, G., Liu, W., Somcio, R., Gray, M. J., Cheng, H., Hoff, P. M., & Ellis, L. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0038 · Cited by 526
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
House, M. G., Ito, H., Gönen, M., Fong, Y., Allen, P. J., DeMatteo, R. P., Brennan, M. F., Blumgart, L. H., Jarnagin, W. R., & D'Angelica, M. I. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.12.040 · Cited by 517
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., & Topolcan, O. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.021 · Cited by 506
Systemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Dalerba, P., Sahoo, D., Paik, S., Guo, X., Yothers, G., Song, N., Wilcox-Fogel, N., Forgó, E., Rajendran, P. S., Miranda, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506597 · Cited by 470
Extracellular Metabolic Energetics Can Promote Cancer Progression
Loo, J. M., Scherl, A., Nguyen, A., Man, F. Y., Weinberg, E., Zeng, Z., Saltz, L., Paty, P. B., & Tavazoie, S. F. (2015) · Cell · doi:10.1016/j.cell.2014.12.018 · Cited by 393
Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., Kerb, R., Blievernicht, J., Fischer, J., Hofmann, U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4182 · Cited by 393
Tumour budding in colorectal carcinoma
Prall, F. (2007) · Histopathology · doi:10.1111/j.1365-2559.2006.02551.x · Cited by 369
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis
Walther, A., Houlston, R., & Tomlinson, I. (2008) · Gut · doi:10.1136/gut.2007.135004 · Cited by 368
Colorectal cancer molecular biology moves into clinical practice
Pritchard, C. C., & Grady, W. M. (2011) · Gut · doi:10.1136/gut.2009.206250 · Cited by 344
Bu, P., Chen, K.-Y., Xiang, K., Johnson, C., Crown, S. B., Rakhilin, N., Ai, Y., Wang, L., Xi, R., Astapova, I., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.003 · Cited by 324
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Fujita, K.-I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12234 · Cited by 323
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
Adjuvant Treatment of Colorectal Cancer
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., & Mayer, R. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.3.168 · Cited by 306
Booth, C. M., Li, G., Zhang‐Salomons, J., & Mackillop, W. J. (2010) · Cancer · doi:10.1002/cncr.25427 · Cited by 289
Liu, T., Zhang, X., Du, L., Wang, Y., Liu, X., Tian, H., Wang, L., Li, P., Zhao, Y., Duan, W., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0981-7 · Cited by 264
RetractedPhysical Activity and Male Colorectal Cancer Survival
Meyerhardt, J. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.412 · Cited by 262
Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007287 · Cited by 259
Fiber Intake and Survival After Colorectal Cancer Diagnosis
Song, M., Wu, K., Meyerhardt, J. A., Ogino, S., Wang, M., Fuchs, C. S., Giovannucci, E. L., & Chan, A. T. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3684 · Cited by 197
Mao, C., Yang, Z. Y., Hu, X. F., Chen, Q., & Tang, J. L. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr464 · Cited by 188
Phenformin as prophylaxis and therapy in breast cancer xenografts
Appleyard, M. V. C. L., Murray, K. E., Coates, P. J., Wullschleger, S., Bray, S. E., Kernohan, N. M., Fleming, S., Alessi, D. R., & Thompson, A. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.56 · Cited by 108
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Expression of standard CD44 in human colorectal carcinoma: Association with prognosis
Huh, J. W., Kim, H. R., Kim, Y. J., Lee, J. H., Park, Y. S., Cho, S. H., & Joo, J. K. (2009) · Pathology International · doi:10.1111/j.1440-1827.2009.02357.x · Cited by 65
Knickelbein, K., Tong, J., Chen, D., Wang, Y.-J., Misale, S., Bardelli, A., Yu, J., & Zhang, L. (2018) · Oncogene · doi:10.1038/s41388-018-0289-x · Cited by 33
Cohen, M. S., Al-kasspooles, M. F., Williamson, S. K., Henry, D., Broward, M., & Roby, K. F. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0669-0 · Cited by 17
Metadata
- Authors
- Varghese, A. M.
- Venue
- DeckerMed CGSO Case-Based Reviews
- Publisher
- Decker Medicine
- Published
- 2019-05-09
- OpenAlex
- W4236891330
- Cited by
- 883
- References
- 15
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.